• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Ocrelizumab-associated severe neutropenia: an underestimated complication of treatment of multiple sclerosis with anti-CD20 antibodies?].

作者信息

Hess Felix, Uibel Paula, Berthele Achim, Hemmer Bernhard

机构信息

Klinik und Poliklinik für Neurologie, Klinikum rechts der Isar der Technischen Universität München, München, Deutschland.

出版信息

Nervenarzt. 2023 Dec;94(12):1153-1156. doi: 10.1007/s00115-023-01507-2. Epub 2023 Jun 9.

DOI:10.1007/s00115-023-01507-2
PMID:37294304
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10252158/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d572/10684407/877d1966207b/115_2023_1507_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d572/10684407/877d1966207b/115_2023_1507_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d572/10684407/877d1966207b/115_2023_1507_Fig1_HTML.jpg

相似文献

1
[Ocrelizumab-associated severe neutropenia: an underestimated complication of treatment of multiple sclerosis with anti-CD20 antibodies?].[奥瑞珠单抗相关的严重中性粒细胞减少症：抗CD20抗体治疗多发性硬化症的一种被低估的并发症？]
Nervenarzt. 2023 Dec;94(12):1153-1156. doi: 10.1007/s00115-023-01507-2. Epub 2023 Jun 9.
2
Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature.奥瑞珠单抗治疗多发性硬化症相关的迟发性绝对中性粒细胞减少症：一例报告及文献复习
J Neurol Sci. 2020 Feb 15;409:116603. doi: 10.1016/j.jns.2019.116603. Epub 2019 Nov 28.
3
Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.奥瑞珠单抗换用利妥昔单抗后，多发性硬化症患者首剂后出现迟发性中性粒细胞减少症。
Mult Scler Relat Disord. 2020 Aug;43:102155. doi: 10.1016/j.msard.2020.102155. Epub 2020 May 13.
4
Viral pericarditis following ocrelizumab in a multiple sclerosis patient.奥瑞珠单抗治疗多发性硬化症患者后并发病毒性心包炎。
Neurol Sci. 2023 Aug;44(8):2947-2949. doi: 10.1007/s10072-023-06782-0. Epub 2023 Apr 25.
5
Dengue fever in a multiple sclerosis patient taking Ocrelizumab.奥瑞珠单抗治疗多发性硬化症患者并发登革热。
Mult Scler. 2021 Nov;27(13):2116-2118. doi: 10.1177/13524585211030214. Epub 2021 Aug 27.
6
Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient.利妥昔单抗和奥瑞珠单抗诱发的1例多发性硬化症患者的早发性和迟发性中性粒细胞减少症
Neurol Sci. 2021 Sep;42(9):3893-3895. doi: 10.1007/s10072-021-05357-1. Epub 2021 Jun 1.
7
Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis.奥瑞珠单抗治疗多发性硬化症后迟发性中性粒细胞减少症
Neurology. 2019 Feb 26;92(9):435-436. doi: 10.1212/WNL.0000000000006924. Epub 2019 Jan 11.
8
Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis.选定复发缓解型多发性硬化症患者使用半剂量奥瑞珠单抗治疗。
Acta Neurol Belg. 2024 Feb;124(1):303-306. doi: 10.1007/s13760-023-02303-0. Epub 2023 Jun 10.
9
Serum sickness in a multiple sclerosis patient treated with ocrelizumab.使用奥瑞珠单抗治疗的多发性硬化症患者发生血清病。
J Neurol. 2024 Feb;271(2):727-728. doi: 10.1007/s00415-023-12082-6. Epub 2023 Oct 31.
10
Two cases of meningitis associated with ocrelizumab therapy.两例与奥瑞珠单抗治疗相关的脑膜炎。
Mult Scler Relat Disord. 2020 Feb;38:101866. doi: 10.1016/j.msard.2019.101866. Epub 2019 Nov 27.

引用本文的文献

1
[Severe late-onset neutropenia after rituximab administration].[利妥昔单抗给药后严重迟发性中性粒细胞减少症]
Z Rheumatol. 2025 Jun 4. doi: 10.1007/s00393-025-01668-2.
2
Severe Late-Onset Neutropenia in a Pregnant Patient with Multiple Sclerosis after Ocrelizumab.接受奥瑞珠单抗治疗的多发性硬化症孕妇出现严重迟发性中性粒细胞减少症。
Case Rep Neurol. 2025 Mar 26;17(1):36-40. doi: 10.1159/000544749. eCollection 2025 Jan-Dec.

本文引用的文献

1
Ocrelizumab-related neutropenia: Effects of age, sex and bodyweight using the FDA Adverse Event Reporting System (FAERS).奥瑞珠单抗相关中性粒细胞减少症：使用 FDA 不良事件报告系统（FAERS）评估年龄、性别和体重的影响。
Mult Scler Relat Disord. 2022 Sep;65:104015. doi: 10.1016/j.msard.2022.104015. Epub 2022 Jul 3.
2
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.奥瑞珠单抗治疗复发型多发性硬化症五年：OPERA研究开放标签扩展
Neurology. 2020 Sep 29;95(13):e1854-e1867. doi: 10.1212/WNL.0000000000010376. Epub 2020 Jul 20.
3
Rituximab associated late-onset neutropenia-a rheumatology case series and review of the literature.
利妥昔单抗相关迟发性中性粒细胞减少症——一个风湿病病例系列及文献综述
Clin Rheumatol. 2016 Oct;35(10):2457-62. doi: 10.1007/s10067-016-3313-y. Epub 2016 May 21.
4
Neutropenia associated with rituximab therapy.与利妥昔单抗治疗相关的中性粒细胞减少症。
Curr Opin Hematol. 2011 Jan;18(1):49-54. doi: 10.1097/MOH.0b013e3283414edf.
5
B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.基于利妥昔单抗的治疗后B细胞恢复与基质衍生因子-1和粒细胞稳态的扰动有关。
Blood. 2005 Aug 1;106(3):795-802. doi: 10.1182/blood-2004-08-3198. Epub 2005 Feb 17.
6
Neutropenia in patients treated with rituximab.接受利妥昔单抗治疗患者的中性粒细胞减少症。
N Engl J Med. 2003 Jun 26;348(26):2691-4; discussion 2691-4. doi: 10.1056/NEJM200306263482620.
7
Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases.
Leuk Res. 2002 Jun;26(6):597-600. doi: 10.1016/s0145-2126(01)00183-7.